Who says that the phenomenal success of blockbuster drugs is mostly eaten away by ‘look-alikes’ of the same, immediately after respective patent expiry? It doesn’t seem to be so any longer, not anymore! Several examples will vindicate this emerging trend. … Continue reading
Tag Archives: expiry
Pharma Outlook 2015: A Glimpse Of Some Drivers and Barriers
Looking ahead, the brand new year 2015 appears quite interesting to me both from the global and also from the local pharmaceutical industry perspective. In this article I shall try to give a glimpse of some of the important drivers … Continue reading
Does Patent Expiry Matter Less For Difficult To Copy Drugs?
“Patent expiry matters much less for difficult to copy drugs”. Not so long ago, this is what many used to believe in the pharma industry. However, looking at the current trend involving the tech savvy generic players, it appears, gone … Continue reading
Sets 2013, Dawns 2014: Top 7 Pharma Developments
Wish You Good Health, Happiness, Success and Prosperity in 2014 In this article I shall focus on ‘Top 7 Pharma Developments’, both while ‘Looking Back to 2013′ and also during my ‘Crystal Gazing 2014′. Looking Back to 2013: While looking … Continue reading
Pharma Horizon: Cloud, Rainbow And Smear
Some recent papers contemplated that the patent cliff for blockbuster drugs has already reached the zenith and early signs of recovery should be visible from 2013 onwards. However, from analysis of the currently available data, contrary to the above belief, I reckon, the downtrend … Continue reading
In the Wonderland of Pharma Generics: Some Steps In, Some Steps Over the Line
To scale-up access to healthcare, especially for the marginalized population of any country, greater access to affordable generic drugs will always remain fundamental, besides improving healthcare infrastructure and its delivery mechanism. Thus, there should be a robust mechanism across the … Continue reading
Explore the Emerging Markets with the ‘Wings of Courage’.
Overall growth rate of the global pharmaceutical industry is currently hovering around 5%. Similar situation has been prevailing since last several years. There is no indication of acceleration of growth rate from any of the top 3 regions of the … Continue reading
The traditional ‘Business Models’ of R&D focused Global Pharmaceutical majors are undergoing a metamorphosis
Mounting pressure on the P&L account, as the products go off patent: Patented new products are the prime growth driver of the research based pharmaceutical companies of the world. Since last few years, because of various reasons, the number of … Continue reading